CORONA REMEDIES Financial Statement Analysis
|
||
|
The Revenues of CORONA REMEDIES have decreased by -88.21% YoY .
The Earnings Per Share (EPS) of CORONA REMEDIES has increased by 23.91 % YoY. |
||
CORONA REMEDIES Last 5 Annual Financial Results
[BOM: 544644|NSE : CORONA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 |
|---|---|---|---|---|
| Revenues | ₹1,196 Cr | ₹10,145 Cr | ₹884 Cr | ₹884 Cr |
| Expenses | ₹956 Cr | ₹8,597 Cr | ₹756 Cr | ₹756 Cr |
| Operating Profit (Excl OI) | ₹240 Cr | ₹1,547 Cr | ₹128 Cr | ₹128 Cr |
| Other Income | ₹5.93 Cr | ₹65 Cr | ₹7.05 Cr | ₹7.05 Cr |
| Interest | ₹11 Cr | ₹144 Cr | ₹4.27 Cr | ₹4.27 Cr |
| Depreciation | ₹37 Cr | ₹283 Cr | ₹20 Cr | ₹20 Cr |
| Profit Before Tax | ₹199 Cr | ₹1,185 Cr | ₹111 Cr | ₹111 Cr |
| Profit After Tax | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
| Consolidated Net Profit | ₹149 Cr | ₹905 Cr | ₹85 Cr | ₹85 Cr |
| Earnings Per Share (Rs) | ₹30.27 | ₹24.43 | ₹14.80 | ₹13.89 |
| PAT Margin (%) | 13.42 | 12.72 | 8.73 | 9.46 |
| ROE(%) | 27.36 | 27.50 | 20.36 | 20.79 |
| ROCE(%) | 31.74 | 32.59 | 25.93 | 28.03 |
| Total Debt/Equity(x) | 0.19 | 0.10 | 0.28 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 12,461.2 Cr |
| Revenue (TTM) | : | ₹ 1,350.3 Cr |
| Net Profit(TTM) | : | ₹ 169.8 Cr |
| EPS (TTM) | : | ₹ 27.7 |
| P/E (TTM) | : | 73.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CORONA REMEDIES | 3.4% | 20% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | 6.4% | 12.1% |
| DIVIS LABORATORIES | 3% | 2.8% | 0.9% |
| TORRENT PHARMACEUTICALS | 2.3% | 9.1% | 44.6% |
| CIPLA | 0.3% | 6.1% | -3.7% |
| DR REDDYS LABORATORIES | -0.1% | 8.9% | 1.9% |
| MANKIND PHARMA | 1.8% | 6.7% | 8% |
| LUPIN | 2.9% | 9.5% | 24.5% |
| ZYDUS LIFESCIENCES | 1.7% | 6% | 12% |
CORONA REMEDIES Revenues
[BOM: 544644|NSE : CORONA]
| Y-o-Y | -88.21 % |
| 5 Yr CAGR | 10.61 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,196 Cr | -88.21 | |
| Mar2025 | ₹10,145 Cr | 1,047.53 | |
| Mar2024 | ₹884 Cr | 0.00 | |
| Mar2023 | ₹884 Cr | - | |
CORONA REMEDIES Operating Profit
[BOM: 544644|NSE : CORONA]
| Y-o-Y | -84.49 % |
| 5 Yr CAGR | 23.31 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹240 Cr | -84.49 | |
| Mar2025 | ₹1,547 Cr | 1,109.05 | |
| Mar2024 | ₹128 Cr | 0.00 | |
| Mar2023 | ₹128 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 31.54 % |
| 5 Yr CAGR | 11.48 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 20.06% | 31.54 | |
| Mar2025 | 15.25% | 5.32 | |
| Mar2024 | 14.48% | 0.00 | |
| Mar2023 | 14.48% | - | |
CORONA REMEDIES Profit After Tax
[BOM: 544644|NSE : CORONA]
| Y-o-Y | -83.49 % |
| 5 Yr CAGR | 20.72 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹149 Cr | -83.49 | |
| Mar2025 | ₹905 Cr | 965.63 | |
| Mar2024 | ₹85 Cr | 0.00 | |
| Mar2023 | ₹85 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 5.50 % |
| 5 Yr CAGR | 12.36 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 13.42 % | 5.50 | |
| Mar2025 | 12.72 % | 45.70 | |
| Mar2024 | 8.73 % | -7.72 | |
| Mar2023 | 9.46 % | - | |
CORONA REMEDIES Earnings Per Share (EPS)
[BOM: 544644|NSE : CORONA]
| Y-o-Y | 23.91 % |
| 5 Yr CAGR | 29.65 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹30 | 23.91 | |
| Mar2025 | ₹24 | 65.07 | |
| Mar2024 | ₹15 | 6.55 | |
| Mar2023 | ₹14 | - | |
CORONA REMEDIES Return on Capital Employed (ROCE)
[BOM: 544644|NSE : CORONA]
| Y-o-Y | -2.61 % |
| 5 Yr CAGR | 4.23 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 31.74% | -2.61 | |
| Mar2025 | 32.59% | 25.68 | |
| Mar2024 | 25.93% | -7.49 | |
| Mar2023 | 28.03% | - | |
CORONA REMEDIES Share Price vs Sensex
| Current Share Price | : | ₹2,036.2 |
| Current MarketCap | : | ₹ 12,461.2 Cr |
| Updated EOD on | : | Jul 03,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 3.4% |
20% |
|
| SENSEX | 0.9% |
4.2% |
-6% |
CORONA REMEDIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 3.1% | 8.2% | 14.9% |
| BSE IPO | 1.4% | 8.1% | 16% |
| BSE 1000 | 0.9% | 3.7% | 0.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY IPO INDEX | 2% | 8.5% | 12.4% |
| NIFTY MICROCAP 250 | 1.5% | 7.1% | 6.1% |
| NIFTY TOTAL MARKET | 0.8% | 3.6% | 0.3% |
You may also like the below Video Courses
FAQ about CORONA REMEDIES Financials
How the annual revenues of CORONA REMEDIES have changed ?
The Revenues of CORONA REMEDIES have decreased by -88.21% YoY .
How the Earnings per Share (EPS) of CORONA REMEDIES have changed?
The Earnings Per Share (EPS) of CORONA REMEDIES has increased by 23.91 % YoY .
Check out Intrinsic Value of Peers of CORONA REMEDIES
Compare Stock Analytics of Peers of CORONA REMEDIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
